ArticleCurrent pharmaceutical design2025
Identification of Ferroptosis-related Genes for Diabetic Nephropathy by Bioinformatics and Experimental Validation.
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research Progress on Elesclomol-Induced Cuproptosis for Antitumor Effects.Biomedicines · 2026Review
- High glucose-induced PLCG1 histone acetylation to promote ferroptosis by LAMP2A/HSPA8 in a diabetic nephropathy model.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThe present study delves into the exploration of diagnostic biomarkers linked with ferroptosis in the context of diabetic nephropathy, unraveling their underlying molecular mechanisms.
methodsIn this study, we retrieved datasets GSE96804 and GSE30529 as the training cohort, followed by screening for Differentially Expressed Genes (DEGs). By intersecting these DEGs with known ferroptosisrelated genes, we obtained the differentially expressed genes related to ferroptosis (DEFGs). Subsequently, Weighted Correlation Network Analysis (WGCNA) was carried out to identify key modules associated with Diabetic Nephropathy (DN), culminating in the identification of a significant gene. Enrichment analysis and Gene Set Enrichment Analysis (GSEA) were then carried out on the DEFGs and genes linked to the significant gene. To validate our findings, we employed cohorts GSE30528 and GSE43950, utilizing ROC curve analysis to assess diagnostic efficacy for DN, as measured by the area under the curve (AUC). Immune cell infiltration was analyzed and compared between groups using the CIBERSORT algorithm. Bayesian colocalization analysis was performed to examine the co-location of DEFGs and DN. Finally, to validate the hub genes identified, we conducted quantitative real-time polymerase chain reaction (qRT-PCR) experiments
resultsFUZ, GLI1, GLI2, GLI3, and DVL2 were identified as the hub genes. Functional enrichment analysis demonstrated that ferroptosis and immune response play an important role in DN. ROC analysis showed that the identified genes had good diagnostic efficiency in DN. The results of the immune infiltration analysis showed that there may be crosstalk between ferroptosis and immune cells in DN. Bayesian co-localization analysis revealed the genetic correlation between the hub genes and DN. The outcomes of the qRT-PCR analyses corroborated the reliability of the identified hub genes as robust molecular markers for targeted therapy in DN.
conclusionThe interplay between immune inflammatory reactions and ferroptosis emerges as a crucial pathogenic mechanism, offering novel insights into the molecular therapy of DN. Furthermore, the identification of FUZ, GLI1, GLI2, GLI3, and DVL2 as potential targets holds promise for future therapeutic interventions aimed at treating DN.
Indexed as
Identifiers
39865825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.